Regeneron(US:REGN) Globenewswireยท2025-09-04 20:05Core Viewpoint - Regeneron Pharmaceuticals, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 7:00 a.m. ET [1] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing life-transforming medicines for serious diseases [3] - The company was founded and is led by physician-scientists, emphasizing its ability to translate scientific research into approved treatments and product candidates [3] - Regeneron's medicines and pipeline target various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies, such as VelociSuite, to produce optimized fully human antibodies and new classes of bispecific antibodies [4] - The company is advancing drug development through data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms [4] - These innovations enable Regeneron to identify innovative targets and complementary approaches for potentially treating or curing diseases [4]